Evidence map›Paper›PMID 25120040›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2015

Non-small-cell lung cancer resectability: diagnostic value of PET/MR.

Francesco Fraioli, Nicholas J Screaton, Samuel M Janes, Thida Win, Leon Menezes, Irfan Kayani, Rizwan Syed, Fulvio Zaccagna, Celia O'Meara, Anna Barnes and 3 more

Abstract readEvaluation Study
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Diagnostic potential of [Japanese journal of radiology · 2024
    Pooled it
  2. Diagnostic performance of whole-body [European radiology · 2024
    Pooled it
  3. [Frontiers in medicine · 2024
    Pooled it
  4. Prospective comparison ofEuropean journal of nuclear medicine and molecular imaging · 2019
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review.European journal of nuclear medicine and molecular imaging · 2021
    Review
  10. Review
  11. Article
  12. Review
  13. FDG Whole-Body PET/MRI in Oncology: a Systematic Review.Nuclear medicine and molecular imaging · 2017
    Review
  14. Thoracic staging withEuropean radiology · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016
    Review
  19. PET/MRI in Oncological Imaging: State of the Art.Diagnostics (Basel, Switzerland) · 2015
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesco FraioliDepartment of Nuclear Medicine and Radiology, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK, fraioli.francesco@gmail.com.
Nicholas J Screaton
Samuel M Janes
Thida Win
Leon Menezes
Irfan Kayani
Rizwan Syed
Fulvio Zaccagna
Celia O'Meara
Anna Barnes
Jamshed B Bomanji
Shonit Punwani
Ashley M Groves

Funding

Cancer Research UK 16463Wellcome Trust 091730
6 · The paper itself

Abstract

purposeTo assess the diagnostic performance of PET/MR in patients with non-small-cell lung cancer.

methodsFifty consecutive consenting patients who underwent routine (18)F-FDG PET/CT for potentially radically treatable lung cancer following a staging CT scan were recruited for PET/MR imaging on the same day. Two experienced readers, unaware of the results with the other modalities, interpreted the PET/MR images independently. Discordances were resolved in consensus. PET/MR TNM staging was compared to surgical staging from thoracotomy as the reference standard in 33 patients. In the remaining 17 nonsurgical patients, TNM was determined based on histology from biopsy, imaging results (CT and PET/CT) and follow-up. ROC curve analysis was used to assess accuracy, sensitivity and specificity of the PET/MR in assessing the surgical resectability of primary tumour. The kappa statistic was used to assess interobserver agreement in the PET/MR TNM staging. Two different readers, without knowledge of the PET/MR findings, subsequently separately reviewed the PET/CT images for TNM staging. The generalized kappa statistic was used to determine intermodality agreement between PET/CT and PET/MR for TNM staging.

resultsROC curve analysis showed that PET/MR had a specificity of 92.3 % and a sensitivity of 97.3 % in the determination of resectability with an AUC of 0.95. Interobserver agreement in PET/MR reading ranged from substantial to perfect between the two readers (Cohen's kappa 0.646 - 1) for T stage, N stage and M stage. Intermodality agreement between PET/CT and PET/MR ranged from substantial to almost perfect for T stage, N stage and M stage (Cohen's kappa 0.627 - 0.823).

conclusionIn lung cancer patients PET/MR appears to be a robust technique for preoperative staging.

Indexed as

Multimodal ImagingPositron-Emission TomographyAdultAgedCarcinoma, Non-Small-Cell LungFemaleFluorodeoxyglucose F18HumansLung NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingObserver VariationPreoperative PeriodRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID25120040
PMCPMC4244545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.